Next Article in Journal
Two Common Bean Genotypes with Contrasting Response to Phosphorus Deficiency Show Variations in the microRNA 399-Mediated PvPHO2 Regulation within the PvPHR1 Signaling Pathway
Next Article in Special Issue
Surgical Resection of Brain Metastases—Impact on Neurological Outcome
Previous Article in Journal
Inhibition of Corneal Neovascularization with the Combination of Bevacizumab and Plasmid Pigment Epithelium-Derived Factor-Synthetic Amphiphile INTeraction-18 (p-PEDF-SAINT-18) Vector in a Rat Corneal Experimental Angiogenesis Model
Previous Article in Special Issue
Brain Metastasis in Pancreatic Cancer
Int. J. Mol. Sci. 2013, 14(4), 8306-8327; doi:10.3390/ijms14048306
Article

Development of a Preclinical Therapeutic Model of Human Brain Metastasis with Chemoradiotherapy

1,2
, 1
, 3
, 3
 and 1,*
Received: 30 November 2012; in revised form: 16 March 2013 / Accepted: 26 March 2013 / Published: 16 April 2013
(This article belongs to the Special Issue Brain Metastasis)
View Full-Text   |   Download PDF [2003 KB, uploaded 19 June 2014]   |   Browse Figures
Abstract: Currently, survival of breast cancer patients with brain metastasis ranges from 2 to 16 months. In experimental brain metastasis studies, only 10% of lesions with the highest permeability exhibited cytotoxic responses to paclitaxel or doxorubicin. Therefore, radiation is the most frequently used treatment, and sensitizing agents, which synergize with radiation, can improve the efficacy of the therapy. In this study we used 435-Br1 cells containing the fluorescent protein (eGFP) gene and the photinus luciferase (PLuc) gene to develop a new brain metastatic cell model in mice through five in vivo/in vitro rounds. BR-eGFP-CMV/Luc-V5 brain metastatic cells induce parenchymal brain metastasis within 60.8 ± 13.8 days of intracarotid injection in all mice. We used this model to standardize a preclinical chemoradiotherapy protocol comprising three 5.5 Gy fractions delivered on consecutive days (overall dose of 16.5 Gy) which improved survival with regard to controls (60.29 ± 8.65 vs. 47.20 ± 11.14). Moreover, the combination of radiotherapy with temozolomide, 60 mg/Kg/day orally for five consecutive days doubled survival time of the mice 121.56 ± 52.53 days (Kaplan-Meier Curve, p < 0.001). This new preclinical chemoradiotherapy protocol proved useful for the study of radiation response/resistance in brain metastasis, either alone or in combination with new sensitizing agents.
Keywords: brain metastasis; breast cancer; experimental models; radiation; temozolomide; therapy brain metastasis; breast cancer; experimental models; radiation; temozolomide; therapy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Martínez-Aranda, A.; Hernández, V.; Picón, C.; Modolell, I.; Sierra, A. Development of a Preclinical Therapeutic Model of Human Brain Metastasis with Chemoradiotherapy. Int. J. Mol. Sci. 2013, 14, 8306-8327.

AMA Style

Martínez-Aranda A, Hernández V, Picón C, Modolell I, Sierra A. Development of a Preclinical Therapeutic Model of Human Brain Metastasis with Chemoradiotherapy. International Journal of Molecular Sciences. 2013; 14(4):8306-8327.

Chicago/Turabian Style

Martínez-Aranda, Antonio; Hernández, Vanessa; Picón, Cristina; Modolell, Ignasi; Sierra, Angels. 2013. "Development of a Preclinical Therapeutic Model of Human Brain Metastasis with Chemoradiotherapy." Int. J. Mol. Sci. 14, no. 4: 8306-8327.


Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert